###begin article-title 0
###xml 22 23 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 104 108 <span type="species:ncbi:10090">mice</span>
###xml 113 119 <span type="species:ncbi:9606">humans</span>
Small intestinal CD103+ dendritic cells display unique functional properties that are conserved between mice and humans
###end article-title 0
###begin p 1
###xml 30 53 30 53 <email xmlns:xlink="http://www.w3.org/1999/xlink">William.Agace@med.lu.se</email>
CORRESPONDENCE William Agace: William.Agace@med.lu.se
###end p 1
###begin p 2
This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see ). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at ).
###end p 2
###begin p 3
###xml 39 40 39 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 158 159 158 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 394 395 387 388 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 406 407 399 400 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 555 556 548 549 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 587 588 580 581 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 633 634 626 627 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 778 779 771 772 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 787 788 780 781 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 821 822 814 815 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 975 976 968 969 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1123 1124 1116 1117 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1196 1197 1189 1190 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 95 101 <span type="species:ncbi:10090">murine</span>
###xml 1046 1051 <span type="species:ncbi:9606">human</span>
###xml 1158 1166 <span type="species:ncbi:9606">patients</span>
###xml 1252 1257 <span type="species:ncbi:9606">human</span>
A functionally distinct subset of CD103+ dendritic cells (DCs) has recently been identified in murine mesenteric lymph nodes (MLN) that induces enhanced FoxP3+ T cell differentiation, retinoic acid receptor signaling, and gut-homing receptor (CCR9 and alpha4beta7) expression in responding T cells. We show that this function is specific to small intestinal lamina propria (SI-LP) and MLN CD103+ DCs. CD103+ SI-LP DCs appeared to derive from circulating DC precursors that continually seed the SI-LP. BrdU pulse-chase experiments suggested that most CD103+ DCs do not derive from a CD103- SI-LP DC intermediate. The majority of CD103+ MLN DCs appear to represent a tissue-derived migratory population that plays a central role in presenting orally derived soluble antigen to CD8+ and CD4+ T cells. In contrast, most CD103- MLN DCs appear to derive from blood precursors, and these cells could proliferate within the MLN and present systemic soluble antigen. Critically, CD103+ DCs with similar phenotype and functional properties were present in human MLN, and their selective ability to induce CCR9 was maintained by CD103+ MLN DCs isolated from SB Crohn's patients. Thus, small intestinal CD103+ DCs represent a potential novel target for regulating human intestinal inflammatory responses.
###end p 3
###begin p 4
Abbreviations used: LP, lamina propria; MLN, mesenteric LN; pOVA, OVA peptide; PP, Peyer's patch; RA; retinoic acid; RAR, retinoic acid receptor; SI, small intestine; SI-LP, small intestinal LP; SILT, solitary isolated lymphoid tissue.
###end p 4
###begin p 5
###xml 92 93 92 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 95 96 95 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 330 331 326 327 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 334 335 330 331 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 342 343 338 339 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 346 347 342 343 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 356 357 348 349 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 368 369 360 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 378 379 366 367 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 433 434 421 422 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 443 444 431 432 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 452 453 440 441 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 462 463 446 447 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 469 471 453 455 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lo</sup>
###xml 564 565 548 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">3</xref>
###xml 567 568 551 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 740 741 724 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 743 744 727 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 841 842 825 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 844 845 828 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 846 848 830 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 99 105 <span type="species:ncbi:10090">Murine</span>
###xml 831 836 <span type="species:ncbi:9606">human</span>
###xml 938 943 <span type="species:ncbi:9606">human</span>
###xml 1052 1057 <span type="species:ncbi:9606">human</span>
DCs are well recognized for their role in the priming and differentiation of naive T cells (1, 2). Murine conventional DCs have been extensively studied and have traditionally been divided into five distinct subsets based on their expression of CD11b, CD4, CD8alpha, and Langerin. The spleen contains three of these subsets (CD11b+CD4+, CD11b+CD4- CD8alpha-, and CD11b- CD8alpha+), whereas LNs contain two additional populations (CD4- Langerin+ and CD4- CD8alpha- CD11blo) that display a more mature phenotype and appear to represent tissue-derived migratory DCs (3, 4). Although the developmental relationships between these populations remains unclear, several of these subsets have been described to have distinct functional properties (5, 6). Nevertheless, surprisingly few studies have attempted to characterize DC subsets in human LN (4, 7-10) and, thus, the possibility of targeting distinct conventional DC subsets for regulating human immune responses remains unclear. Indeed, to our knowledge functionally distinct conventional DC subsets in human LN have yet to be described.
###end p 5
###begin p 6
###xml 518 520 518 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 657 658 657 658 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 808 809 801 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 811 813 804 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 814 816 807 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 1077 1078 1070 1071 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1209 1210 1202 1203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 1212 1214 1205 1207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 1215 1217 1208 1210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 584 590 <span type="species:ncbi:10090">murine</span>
Recent evidence suggests that the tissue environment in which DCs reside has a major impact on their phenotypic and functional properties. This is particularly apparent in the intestinal mucosa. Intestinal DCs are located throughout the villus lamina propria (LP) and in intestinal lymphoid tissue (Peyers Patches [PP], solitary isolated lymphoid tissue [SILT], and mesenteric LN [MLN]), where they play a central role in sampling and processing luminal as well as peripheral self antigen for presentation to T cells (11). Several functional properties have recently been ascribed to murine intestinal DCs. These include an enhanced ability to promote FoxP3+ regulatory T cell and IgA-secreting B cell differentiation and induction of gut-homing receptors (CCR9 and alpha4beta7) on responding T and B cells (8, 12-17). Remarkably, these diverse functions appear, at least in part, to be driven through intestinal DC-mediated retinoic acid receptors (RAR) signaling. Thus, the vitamin A metabolite retinoic acid (RA) induces expression of gut-homing receptors and enhances FoxP3+ T cell and IgA B cell differentiation, whereas RAR antagonists block the ability of intestinal DCs to generate these populations (8, 18-20).
###end p 6
###begin p 7
###xml 150 151 146 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 185 187 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 188 190 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 198 199 194 195 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 233 240 229 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">aldh1a2</italic>
###xml 268 270 264 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 359 360 355 356 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 406 407 402 403 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 509 510 505 506 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 520 522 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 579 580 575 576 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 590 591 586 587 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 902 903 898 899 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 849 854 <span type="species:ncbi:9606">human</span>
###xml 946 952 <span type="species:ncbi:9606">humans</span>
Only a subset of MLN DCs, which express the integrin alpha chain CD103, are efficient at inducing gut-homing receptors on responding T cells and FoxP3+ T cell differentiation in vitro (15-17). CD103+ MLN DCs express higher levels of aldh1a2, the gene encoding RALDH2 (15) which is a key enzyme involved in metabolizing retinal to RA, compared with their CD103- MLN counterparts. Consistent with this, CD103+ MLN DCs induce enhanced RAR dependent signaling in responding T cells, compared with splenic or CD103- MLN DCs (21). Despite these findings, the relationship between CD103+ and CD103- MLN DC subsets and the functional properties of these subsets in other tissues, including the small intestinal and colonic LP, remains unknown. Critically, it also remains to be determined whether these cells represent a functionally distinct population in human MLN and, thus, the potential of targeting CD103+ DCs for regulating intestinal immunity in humans is unclear.
###end p 7
###begin title 8
RESULTS
###end title 8
###begin title 9
###xml 40 41 40 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
Murine small intestinal LP and MLN CD103+ DCs are unique in their capacity to efficiently induce CCR9 and RAR signaling in responding T cells
###end title 9
###begin p 10
###xml 5 6 5 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 96 104 96 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 A</xref>
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 136 137 136 137 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 147 148 147 148 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 243 244 243 244 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 249 251 249 251 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lo</sup>
###xml 274 275 274 275 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 493 494 493 494 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 651 652 651 652 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 674 675 674 675 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 743 744 743 744 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 754 755 754 755 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 922 923 922 923 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 938 939 938 939 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 988 996 988 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 1004 1005 1004 1005 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1082 1083 1082 1083 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1096 1097 1096 1097 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1107 1108 1107 1108 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1167 1182 1167 1182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, B and C</xref>
###xml 1283 1284 1276 1277 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1325 1326 1318 1319 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1393 1394 1379 1380 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1423 1424 1409 1410 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1642 1643 1621 1622 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1794 1795 1773 1774 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1805 1806 1784 1785 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1862 1864 1841 1843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 2167 2168 2146 2147 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2202 2203 2181 2182 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2368 2369 2347 2348 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2379 2387 2358 2366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 2395 2396 2374 2375 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2507 2508 2486 2487 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2597 2605 2576 2584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 2957 2958 2936 2937 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2968 2969 2947 2948 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2999 3000 2978 2979 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 50 56 <span type="species:ncbi:10090">murine</span>
CD103+ DCs are present in a wide range of mucosal murine tissues and secondary lymphoid organs (Fig. 1 A; 15, 17, 22-25). Although CD103+ and CD103- DCs isolated from mucosal tissues (small intestine LP [SI-LP], colonic LP, and lung) were CCR7- CD40lo, the majority of CD103+ DCs in LN (MLN, lung draining mediastinal LN, and peripheral [axillary and brachial] LN) expressed CCR7 and high levels of CD40 and, thus, displayed a more mature phenotype than their peripheral counterparts and CD103- LN DCs (Fig. S1, A and B, available at ; and not depicted). To determine whether the ability to efficiently induce CCR9 on T cells is a feature of all CD103+ DCs, CFSE-labeled CD8+OT-I cells were primed with OVA peptide (pOVA; 2000 pM)-pulsed CD103+ and CD103- DCs from MLN, SI-LP, Colonic-LP, PP, and lung-draining LNs, and expression of tissue-homing receptors on responding T cells was assessed 6 d later. As expected, CD103+, but not CD103-, MLN DCs induced CCR9 on responding OT-I cells (Fig. 1 C). CD103+ SI-LP DCs also efficiently induced CCR9 on responding T cells, whereas CD103- SI-LP, CD103+ and CD103- colonic LP, PP, and lung-draining LN DCs failed to do so (Fig. 1, B and C). In contrast, all DC populations induced some alpha4beta7 on responding OT-I cells (Fig. S2). CD103+ DCs and, in particular, intestinal CD103+ DCs induced higher levels of alpha4beta7 compared with their CD103- counterparts. Although CD103- DCs induced less alpha4beta7 expression, they were more efficient at inducing E-selectin ligand (which is required for effector cell migration to extraintestinal sites of inflammation) on responding T cells than CD103+ DCs, irrespective of their tissue origin (Fig. S2). We have recently demonstrated that OT-I cells express higher levels of CCR9 when primed with CD103+ and CD103- MLN DCs that have been pulsed with a low-dose peptide (21). Because CCR9 expression by OT-I cells, in addition to DCs, is also regulated by antigen dose, we next determined the ability of the different DC preparations to induce expression of CCR9 at a lower and more permissive peptide dose. When we pulsed DCs with a 10-fold lower peptide dose (200 pM), CD103+ PP and, to a lesser extent, CD103- PP DCs induced CCR9 on responding T cells, although the percentage of cells expressing CCR9 remained significantly lower than that observed after priming with CD103+ MLN DCs (Fig. 1 C). CD103+ colonic LP and lung-draining LN DCs also induced limited CCR9 expression under these conditions, whereas CD103- colonic LP, lung-draining LN, and splenic DC subsets failed to efficiently induce CCR9 (Fig. 1 C and not depicted). Thus, although the mechanism underlying the antigen dose-dependent regulation of CCR9 expression by OT-I cells and whether CCR9 expression is influenced by antigen dose in other TCR transgenic systems are currently not known, these results demonstrate that at a lower peptide dose, there is also an inherent difference between CD103+ and CD103- DCs, as well as between CD103+ DCs derived from different tissues, in their ability to efficiently confer CCR9 expression to OT-I cells.
###end p 10
###begin p 11
###xml 33 34 33 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 0 117 0 117 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Small intestinal LP and MLN CD103<sup>+</sup> DCs are unique in their capacity to efficiently induce CCR9 on responding T cells.</bold>
###xml 153 154 153 154 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 159 160 159 160 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 322 323 322 323 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 333 334 333 334 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 431 438 431 438 <sub xmlns:xlink="http://www.w3.org/1999/xlink">257&#8211;264</sub>
###xml 678 679 678 679 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 689 690 689 690 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 765 772 765 772 <sub xmlns:xlink="http://www.w3.org/1999/xlink">257&#8211;264</sub>
###xml 933 934 933 934 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1319 1320 1318 1319 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 285 289 <span type="species:ncbi:10090">mice</span>
Small intestinal LP and MLN CD103+ DCs are unique in their capacity to efficiently induce CCR9 on responding T cells. (A) Percentage of DCs (MHC class II+CD11c+) expressing CD103 in indicated organs. Results are the mean and SD from three to eight independent experiments (two to five mice per experiment). (B and C) CD103+ and CD103- DCs were sorted from the indicated organs by FACS, pulsed with 2 nM (B and C) or 200 pM (C) pOVA257-264, and incubated with OT-I cells. CCR9 expression on responding OT-I cells was assessed after 6 d by flow cytometry. Representative FACS plots (B) and mean and SD (C) of the indicated number of separate experiments are shown. (D and E) CD103+ and CD103- DCs were sorted from the indicated organs by FACS, pulsed with 200 pM pOVA257-264, and incubated with DR5.OT-I cells. Luciferase activity was determined after 22 h of culture. Data are normalized to the luciferase expression observed in CD103+ MLN DC:DR5.OT-I cell cultures within each experiment. -, DR5.OT-I cells alone. Results are the mean and SD of the indicated number of separate experiments. (E) Luciferase activity was blocked when 1 muM of the pan-RAR antagonist LE540 was added to MLN DC-T cell cultures. Results are the mean and SD of three experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001 (compared with CD103+ MLN DCs). LDLN, Lung draining LN; Co-LP, colonic LP.
###end p 11
###begin p 12
###xml 5 6 5 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 31 38 31 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">aldh1a2</italic>
###xml 65 66 65 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 76 78 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 141 142 141 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 253 255 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 481 483 481 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 529 530 529 530 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 539 540 539 540 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 615 623 615 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 D</xref>
###xml 822 824 822 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 832 833 832 833 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 926 927 926 927 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 957 965 957 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 D</xref>
###xml 986 987 986 987 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1046 1047 1046 1047 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1057 1065 1057 1065 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 D</xref>
###xml 1217 1225 1217 1225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 E</xref>
###xml 1254 1255 1254 1255 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1269 1270 1269 1270 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1399 1400 1399 1400 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1492 1493 1492 1493 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1707 1708 1700 1701 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1757 1758 1750 1751 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 371 386 <span type="species:ncbi:10090">transgenic mice</span>
CD103+ MLN DCs express greater aldh1a2 levels compared with CD103- MLN DCs (15), and their efficiency in inducing CCR9 and, presumably, Foxp3+ T reg cell differentiation lies, at least in part, in an enhanced ability to induce RAR signaling in T cells (21). To determine whether CCR9 induction correlated with enhanced DC-mediated RAR signaling, OT-I cells from OT-I.DR5 transgenic mice (which express luciferase under control of three RA response element (DR5) repeats [reference 21]) were primed with pOVA (200 pM)-pulsed CD103+ or CD103- DCs, and luciferase activity in responding cells was assessed after 22 h (Fig. 1 D) at a time when OT-I cells have yet to divide (not depicted). We have previously demonstrated that DCs pulsed with 2,000 or 200 pM pOVA induce similar levels of RAR signaling in responding T cells (21). CD103+ MLN DCs induced significantly greater luciferase activity in OT-I.DR5 cells than their CD103+ PP and colonic counterparts (Fig. 1 D). In contrast, CD103+ SI-LP DCs induced similar levels of RAR signaling as CD103+ MLN DCs (Fig. 1 D). DC-induced luciferase activity was dependent on RAR signaling, as it was inhibited by addition of the pan-RAR antagonist LE540 to the cell cultures (Fig. 1 E). Thus, the ability of CD103+ MLN and SI-LP+ DCs to efficiently induce CCR9 correlates with an enhanced ability to induce RAR signaling in responding T cells. Although CD103+ DCs in general appeared to induce slightly enhanced luciferase activity compared with CD103- DCs (consistent with their enhanced ability to induce alpha4beta7), these results demonstrate that the ability to induce high levels of RAR signaling and efficient CCR9 induction is not a general property of CD103+ DCs or intestinal DCs but is selective for CD103+ DCs that reside in the SI-LP and MLN.
###end p 12
###begin title 13
CD103 is not required for intestinal DCs' ability to generate gut tropic T cells
###end title 13
###begin p 14
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 350 352 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 354 356 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
###xml 386 387 386 387 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 489 492 489 492 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 597 603 590 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 652 655 645 648 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 500 504 <span type="species:ncbi:10090">mice</span>
The results in the previous section clearly demonstrate that CD103 signaling is not sufficient to imprint DCs with the ability to efficiently induce CCR9 and enhanced RAR signaling in responding T cells. However, it remained possible that CD103-mediated adhesion to E-cadherin on epithelial cells (26) or putative ligands in the small intestinal LP (27, 28) was required to expose CD103+ DCs sufficiently to imprinting signals. To assess this possibility, antigen-pulsed MLN DCs from CD103-/- and WT mice were assessed for their ability to induce CCR9 and alpha4beta7 on responding DO11.10 cells (Fig. 2). From these experiments, it is clear that CD103-/- MLN DCs are as efficient as WT MLN DCs at inducing CCR9. Thus, CD103 is simply a marker of DCs in the SI-LP and MLN that have an enhanced ability to induce RAR signaling in responding T cells.
###end p 14
###begin p 15
###xml 0 99 0 99 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CD103 is not required for imprinting MLN DCs with the ability to induce CCR9 on responding T cells.</bold>
###xml 102 103 102 103 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 129 132 129 132 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 179 180 179 180 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 202 206 202 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SCID</italic>
###xml 210 211 210 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 140 144 <span type="species:ncbi:10090">mice</span>
###xml 391 395 <span type="species:ncbi:10090">mice</span>
CD103 is not required for imprinting MLN DCs with the ability to induce CCR9 on responding T cells. 105 MLN DCs from WT and CD103-/- BALB/c mice were cultured together with 2 x 105 CFSE-labeled DO11.10 SCID CD4+ cells, and OVA and expression of CCR9 and alpha4beta7 was assessed 6 (experiment 1 [Expt. 1]) or 7 (experiment 2) d later. (A) Representative FACS plots. (B) Mean and SD of three mice per group for both experiments.
###end p 15
###begin title 16
###xml 5 6 5 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
CD103+ SI-LP DCs derive from DC precursors that continually seed the intestinal LP
###end title 16
###begin p 17
###xml 92 94 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 95 97 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
###xml 139 140 139 140 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 150 151 150 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 250 251 250 251 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 311 312 311 312 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 336 337 336 337 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 343 344 343 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 462 463 462 463 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 469 470 469 470 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 480 481 480 481 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 525 533 525 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 584 585 582 583 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 605 606 603 604 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 715 716 709 710 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 736 737 730 731 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 823 831 817 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 838 839 832 833 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 845 846 839 840 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 866 867 860 861 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 902 910 896 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 B</xref>
###xml 958 959 952 953 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 969 970 963 964 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1011 1012 1005 1006 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1080 1081 1074 1075 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1171 1172 1165 1166 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1209 1210 1203 1204 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1476 1478 1470 1472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
###xml 1536 1538 1530 1532 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 1543 1544 1537 1538 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1665 1673 1659 1667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 C</xref>
###xml 1846 1854 1840 1848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 C</xref>
###xml 389 393 <span type="species:ncbi:10090">Mice</span>
###xml 1433 1437 <span type="species:ncbi:10090">mice</span>
###xml 1470 1474 <span type="species:ncbi:10090">mice</span>
CD103 is induced on activated T cells subsequent to their entry into the intestinal mucosa (29-31). Given the differential ability of CD103+ and CD103- SI-LP DCs to induce an RAR signal and CCR9 on responding T cells, we next determined whether CD103+ SI-LP DCs derive directly from a DC precursor or from CD103- SI-LP DCs (MHC class II+ CD11c+ cells) that up-regulate CD103 in the SI-LP. Mice received a single injection of BrdU i.p., and the percentage of BrdU+ CD103+ and CD103- DCs in the SI-LP was determined over time (Fig. 3 A). 3 h after BrdU injection, 8% (+/- 5.1%) of CD103+ SI-LP DCs were BrdU+, and this number increased to 16% (+/- 6.5%) by 9 h before leveling off. In contrast, 7% (+/- 2.0%) of CD103- SI-LP DCs were BrdU+ at 3 h, and this percentage increased only slightly over the subsequent 24-h period (Fig. 3 A). BrdU+ CD103+ SI-LP DCs were Ki67- and, thus, not actively dividing (Fig. 3 B). Thus, there is a rapid turnover of both CD103+ and CD103- DCs in the SI-LP. Further, because CD103+ SI-LP DCs incorporated BrdU with at least as fast kinetics as CD103- DCs (even at 90 min after injection; not depicted), it appears that the majority of CD103+ SI-LP DCs do not derive from a CD103- SI-LP DC intermediate but from an actively proliferating DC precursor population. To examine whether the villus SI-LP DC compartment is replenished by blood-derived or tissue-resident DC precursors, SI from C57BL/6.CD45.2 mice was grafted into C57BL/6.CD45.1 mice (32). The proportions of host- and graft-derived MHC class IIhiCD11c+ DCs were then determined in the small intestinal mucosa of the graft and host after 6 and 45 d by immunohistochemistry (Fig. 3 C). At both time points, almost all DCs in the small intestinal villi of the grafted intestine were of host origin and at similar levels to those found in the host's own SI (Fig. 3 C). Together, these results suggest that the SI-villus DC compartment is not maintained by tissue resident precursors but from DC precursors that continually seed the SI-LP from the circulation.
###end p 17
###begin p 18
###xml 31 32 31 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 42 43 42 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 0 47 0 47 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Turnover of SI-LP and MLN CD103<sup>+</sup> and CD103<sup>&#8722;</sup> DC.</bold>
###xml 118 119 118 119 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 125 126 125 126 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 136 137 136 137 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 155 156 155 156 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 161 162 161 162 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 448 449 448 449 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 459 460 459 460 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 478 479 478 479 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 485 486 485 486 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 635 636 635 636 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 678 679 678 679 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 723 725 723 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
###xml 955 956 955 956 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 968 970 968 970 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 975 976 975 976 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1058 1059 1057 1058 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1071 1073 1070 1072 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 1148 1149 1147 1148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 52 56 <span type="species:ncbi:10090">Mice</span>
###xml 321 325 <span type="species:ncbi:10090">mice</span>
###xml 637 641 <span type="species:ncbi:10090">mice</span>
###xml 1154 1158 <span type="species:ncbi:10090">mice</span>
Turnover of SI-LP and MLN CD103+ and CD103- DC. (A) Mice were injected i.p. with 2 mg BrdU, and the percentage of BrdU+ CD103+ and CD103- DCs (MHC class II+CD11c+) in the SI-LP and MLN was determined by flow cytometry at the times indicated. Results are the mean and SD of three to seven independent experiments with two mice in each time point except the 72-h time point, which was performed once. (B) BrdU and Ki67 staining on SI-LP and MLN CD103+ and CD103- DCs (MHC class II+ CD11c+) was assessed by flow cytometry 3 and 24 h after BrdU injection. Plots are from one representative experiment of three performed. (C) SI from CD45.2+ mice (graft) was transplanted into CD45.1+ recipients (host) as previously described (32). At days 6 and 45, host and graft intestine were sectioned and stained with antibodies to CD45.2 (red), CD11c (blue), and MHC class II (green). Immunohistochemistry of the 45-d graft is shown. Arrows point to host-derived CD45.2-MHC class IIhiCD11c+ DCs. Bar, 25 mum. The graph is percentage of host-derived (CD45.2 negative) CD11c+MHC class IIhi cells in graft and host small intestinal villus. Results are mean and SD (n = 3 mice per group).
###end p 18
###begin title 19
###xml 5 6 5 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 16 17 16 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
CD103+ and CD103- SI-LP DCs are found primarily in villus LP and solitary isolated lymphoid tissue, respectively
###end title 19
###begin p 20
###xml 400 401 400 401 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 411 412 411 412 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 547 549 547 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 557 558 557 558 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 576 578 576 578 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 583 584 583 584 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 642 643 642 643 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 697 705 697 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 771 773 771 773 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 778 779 778 779 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 853 855 853 855 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 860 861 860 861 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 905 906 905 906 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 908 916 908 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B</xref>
###xml 942 943 942 943 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1032 1033 1032 1033 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1046 1050 1046 1050 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lo/&#8722;</sup>
###xml 1093 1101 1093 1101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B</xref>
###xml 1147 1149 1147 1149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
Suspensions of LP cells generated by enzymatic digestion of intestine likely contain DCs from both villus and small-sized lymphoid follicles, which are also referred to as solitary intestinal lymphoid tissue (SILT). Indeed, more than 1,000 SILT are interspersed throughout the small intestinal mucosa, and DCs constitute a major population in these structures. We therefore examined whether the CD103+ and CD103- subsets of DCs in our intestinal preparations could be differentially derived from these sites. Consistent with our previous results (17), CD103+ DCs (MHC class IIhiCD11c+ cells) were detected in the villus LP. In addition, CD103+ DCs were observed in the subepithelial dome of SILT (Fig. 4 A). Quantitative analysis demonstrated that almost all MHC class IIhiCD11c+ cells in the villus expressed CD103, whereas the majority of MHC class IIhiCD11c+ cells in the dome region of SILT were CD103- (Fig. 4 B). Of note, numerous CD11c+ cells that failed to stain or stained very weakly with anti-MHC class II antibody (CD11c+ MHC classsIIlo/- cells) were present within the villus LP (Fig. 4 B), which is consistent with previous results (17); however, these cells did not express CD103 and their function and ontogeny remains to be determined.
###end p 20
###begin p 21
###xml 21 22 21 22 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 32 33 32 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 46 47 46 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 52 53 52 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 0 95 0 95 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Localization of CD103<sup>+</sup> and CD103<sup>&#8722;</sup> MHC class II<sup>+</sup>CD11c<sup>+</sup> cells within the small intestinal mucosa.</bold>
###xml 336 338 336 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 343 344 343 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 426 428 425 427 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 433 434 432 433 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 522 523 521 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 528 532 <span type="species:ncbi:10090">mice</span>
Localization of CD103+ and CD103- MHC class II+CD11c+ cells within the small intestinal mucosa. (A and B) Expression of CD103 by DCs in small intestinal villus and SILT. (A) Images show overlays of CD103 (red) in combination with CD11c (blue) and MHC class II (green), with insets showing DAPI staining. Arrows point toward MHC class IIhiCD11c+ DCs coexpressing CD103. Bars, 50 mum. (B) The graph is percentage of MHC class IIhiCD11c+ cells in SI villus or dome region of SILT that express CD103. Results are mean and SD (n = 5 mice per group). ***, P < 0.001.
###end p 21
###begin title 22
###xml 21 22 21 22 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 32 33 32 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
The majority of CD103+ and CD103- MLN DCs appear to represent tissue-derived migratory and lymphoid-resident populations, respectively
###end title 22
###begin p 23
###xml 18 19 18 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 61 62 61 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 90 91 90 91 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 160 161 160 161 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 198 199 198 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 209 210 209 210 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 315 316 315 316 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 322 323 322 323 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 333 334 333 334 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 378 379 378 379 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 385 386 385 386 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 492 500 492 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 562 563 562 563 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 670 672 670 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 674 676 674 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">33</xref>
###xml 726 727 726 727 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 733 734 733 734 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 880 888 880 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 912 913 912 913 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 919 920 919 920 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 943 944 943 944 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 990 998 990 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 B</xref>
###xml 1024 1025 1024 1025 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1048 1049 1048 1049 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1157 1158 1145 1146 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1163 1164 1151 1152 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1307 1308 1295 1296 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1318 1319 1306 1307 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1372 1373 1360 1361 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1451 1452 1439 1440 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 242 246 <span type="species:ncbi:10090">Mice</span>
Because most CD103+ SI-LP DCs appear not to derive from CD103- SI-LP DCs and because CD103+ MLN DCs induced greater RAR signaling in T cells compared with CD103- MLN DCs, we determined whether CD103+ and CD103- were of similar origin in MLN. Mice received a single i.p. injection of BrdU, and the appearance of BrdU+ CD103+ and CD103- DCs in the MLN was assessed over time. BrdU+ CD103+ DCs appeared in the MLN with much slower kinetics than in the SI-LP, with their numbers peaking at 48 h (Fig. 3 A). This is consistent with the idea that the majority of CD103+ DCs in the MLN represent a tissue-derived migratory population that enter the MLN via the afferent lymph (17, 33). In marked contrast, the bulk population of BrdU+ CD103- DCs accumulated within the MLN with similar, if not more rapid, kinetics than in the SI-LP, with their numbers peaking 9 h after BrdU injection (Fig. 3 A). Remarkably, most BrdU+ CD103- MLN DCs were also Ki67+ at 3 h and were thus actively proliferating (Fig. 3 B). The percentage of CD103- MLN DCs that were Ki67+ remained constant (approximately6%) throughout the period of the experiment, whereas the proportion of Ki67- BrdU+ cells increased between 3 and 24 h as BrdU-labeled cells exited the cell cycle. Together, these results demonstrate that the majority of CD103+ and CD103- MLN DCs are of different origin. Although most CD103+ MLN DCs appear to represent a tissue-derived migratory population, most CD103- MLN DCs appear to be maintained through continual and local homeostatic proliferation and, potentially, through recruitment of blood-derived precursors.
###end p 23
###begin title 24
###xml 5 6 5 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 87 88 87 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 96 97 96 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
CD103+ MLN DCs play a key role in presenting orally administered soluble antigen to CD8+ and CD4+ T cells
###end title 24
###begin p 25
###xml 29 30 29 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 40 41 40 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 68 69 68 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 77 78 77 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 97 99 97 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 330 331 330 331 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 341 342 341 342 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 445 446 445 446 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 498 506 498 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 A</xref>
###xml 577 578 577 578 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 728 729 728 729 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 739 740 739 740 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 804 812 804 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 A</xref>
###xml 829 830 829 830 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 896 897 896 897 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 903 911 903 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 A</xref>
###xml 1027 1028 1027 1028 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1036 1037 1036 1037 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1052 1053 1052 1053 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1185 1186 1185 1186 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1298 1301 1298 1301 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1338 1340 1338 1340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 1383 1384 1383 1384 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 243 247 <span type="species:ncbi:10090">mice</span>
###xml 1302 1306 <span type="species:ncbi:10090">mice</span>
Although antigen-pulsed CD103+ and CD103- MLN DCs can both prime CD4+ and CD8+ T cells in vitro (15, 17, 22), their distinct origins suggested that each subset might have distinct antigen-presenting function in vivo. To address this question, mice were immunized with OVA orally, killed 17 h later, and the ability of sorted CD103+ and CD103- MLN DCs to prime OT-I or OT-II T cell was assessed in vitro. After oral OVA administration, only CD103+ MLN DCs induced OT-I and OT-II cell proliferation (Fig. 5 A). To determine whether this was caused by a general inability of CD103- MLN DCs to process and present antigen to T cells, similar experiments were performed after i.p. OVA immunization. Under these conditions, both CD103+ and CD103- MLN DCs were capable of inducing OT-I and OT-II proliferation (Fig. 5 A). Notably, CD103- DCs consistently induced more OT-II cell proliferation than CD103+ DCs (Fig. 5 A and not depicted). Thus, although both DC populations are capable of presenting and cross-presenting antigen to CD8+ and CD4+ T cells, CD103+ MLN DCs are of primary importance in driving T cell responses to orally administered soluble antigen. Because the majority of CD103+ MLN DCs appear to represent an LP-derived migratory population and OT-I cells are not primed in the MLN of CCR7-/- mice after oral OVA administration (17), these results further suggest that CD103+ DC migration from the LP is required to drive T cell responses to luminal soluble antigen in the MLN.
###end p 25
###begin p 26
###xml 5 6 5 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 61 62 61 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 70 71 70 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 0 80 0 80 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CD103<sup>+</sup> DCs present orally administered soluble antigen to CD4<sup>+</sup> and CD8<sup>+</sup> T cells.</bold>
###xml 178 179 178 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 185 186 185 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 196 197 196 197 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 262 263 262 263 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 683 684 676 677 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 694 695 687 688 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 91 95 <span type="species:ncbi:10090">Mice</span>
###xml 484 488 <span type="species:ncbi:10090">mice</span>
CD103+ DCs present orally administered soluble antigen to CD4+ and CD8+ T cells. (A and B) Mice received PBS 5 mg OVA i.p., or 50 mg orally, and MLN were harvested after 17 h. 105 CD103+ and CD103- MLN DCs were isolated by cell sorting and cocultured with 2 x 105 CFSE-labeled OT-I or OT-II cells. (A) CFSE profile of OT-I and OT-II cells 3.5 d after coculture with indicated DCs. Data are representative of three to five separate experiments using MLN DCs isolated from 15-20 pooled mice per group. (B) Expression of CCR9 and alpha4beta7 was analyzed by FACS after 3.5 d in coculture. The graph shows mean and SEM from five independent experiments. *, P < 0.05 (when comparing CD103+ and CD103- DC-primed cultures).
###end p 26
###begin p 27
###xml 172 180 172 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 B</xref>
###xml 211 212 211 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 336 337 329 330 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 343 351 336 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 B</xref>
###xml 392 393 385 386 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 497 498 490 491 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 596 598 589 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 62 66 <span type="species:ncbi:10090">mice</span>
Finally, because both DC subsets isolated from i.p.-immunized mice induced some OT-I cell proliferation, we compared induction of gut-homing receptors on responding cells (Fig. 5 B). OT-I cells primed with CD103+ DCs expressed significantly higher levels of CCR9 and high levels of alpha4beta7 compared with OT-I cells primed with CD103- DCs (Fig. 5 B). The limited induction of CCR9 on CD103- DC-primed OT-I cells likely reflects the level of peptide being presented by these cells, because CD103- MLN DCs pulsed with low peptide dose are capable of inducing some CCR9 on responding OT-I cells (21).
###end p 27
###begin title 28
###xml 5 6 5 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 26 31 <span type="species:ncbi:9606">human</span>
CD103+ DCs are present in human MLN and efficiently induce CCR9 on responding T cells
###end title 28
###begin p 29
###xml 53 54 53 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 122 123 122 123 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 159 160 159 160 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 250 251 250 251 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 287 302 287 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6, A and B</xref>
###xml 372 374 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 388 389 388 389 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 457 458 457 458 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 515 530 515 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6, C and D</xref>
###xml 538 539 538 539 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 624 632 624 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 B</xref>
###xml 671 672 671 672 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 682 683 682 683 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 881 882 874 875 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 915 926 908 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7, A&#8211;C</xref>
###xml 957 958 950 951 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1028 1029 1021 1022 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1054 1055 1047 1048 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1070 1085 1063 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7, A and B</xref>
###xml 1164 1179 1150 1165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7, A and C</xref>
###xml 1233 1234 1219 1220 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1513 1514 1499 1500 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1567 1575 1553 1561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 B</xref>
###xml 1636 1644 1615 1623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 C</xref>
###xml 1704 1705 1676 1677 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1831 1839 1803 1811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 D</xref>
###xml 1970 1971 1942 1943 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 41 47 <span type="species:ncbi:10090">murine</span>
###xml 88 93 <span type="species:ncbi:9606">human</span>
###xml 143 148 <span type="species:ncbi:9606">human</span>
###xml 365 370 <span type="species:ncbi:10090">mouse</span>
###xml 377 382 <span type="species:ncbi:9606">human</span>
###xml 614 622 <span type="species:ncbi:9606">patients</span>
###xml 939 944 <span type="species:ncbi:10090">mouse</span>
###xml 946 951 <span type="species:ncbi:9606">human</span>
###xml 1387 1395 <span type="species:ncbi:9606">patients</span>
###xml 1693 1698 <span type="species:ncbi:9606">human</span>
Finally, to determine whether studies of murine CD103+ MLN DCs were translatable to the human, we determined whether CD103+ DCs are present in human MLN. CD103+ DCs were readily detected in MLN draining the normal SI, although the percentage of CD103+ DCs showed considerable variation (Fig. 6, A and B; for gating strategy see Fig. S3 A, available at ). As in the mouse (17), human CD103+ MLN DCs displayed a more mature phenotype compared with their CD103- counterparts, as judged by expression of CD40 and CD83 (Fig. 6, C and D). CD103+ DCs were also readily detected in MLN draining the inflamed SI of Crohn's patients (Fig. 6 B). To assess the functionality of CD103+ and CD103- MLN DCs, these subsets were purified from pooled MLN draining normal SI (Fig. S3 B) and incubated together with allogeneic CFSE-labeled PBL. The expression of CCR9 and alpha4beta7 on responding CD8+ T cells was assessed after 7 d (Fig. 7, A-C). As in the mouse, human CD103+ MLN DCs induced significantly higher levels of CCR9 on responding CD8+ T cells than their CD103- counterparts (Fig. 7, A and B). In contrast, both DC populations induced similar expression of alpha4beta7 (Fig. 7, A and C). To determine whether the selective ability of CD103+ MLN DCs to induce CCR9 was maintained in chronic small intestinal inflammatory disease, similar studies were performed with sorted MLN DCs from Crohn's patients. Because these LN were considerably enlarged, pooling of LN was not required. As with DCs from normal MLN, only CD103+ DCs efficiently induced CCR9 on responding T cells (Fig. 7 B), whereas both populations efficiently induced alpha4beta7 (Fig. 7 C). Finally, induction of CCR9 and alpha4beta7 by human CD103+ MLN DCs was dependent on RAR signaling as gut-homing receptor expression was inhibited by addition of LE540 to the cultures (Fig. 7 D). Together, these results demonstrate a remarkable cross-species preservation of the phenotypic and functional properties of CD103+ MLN and demonstrate that these functional properties are maintained in Crohn's disease.
###end p 29
###begin p 30
###xml 42 43 42 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 53 54 53 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 0 63 0 63 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Phenotypic characterization of human CD103<sup>+</sup> and CD103<sup>&#8722;</sup> MLN DCs.</bold>
###xml 217 218 217 218 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 464 465 463 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 509 510 508 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 549 550 548 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 600 601 599 600 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 611 612 610 611 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 886 887 885 886 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 31 36 <span type="species:ncbi:9606">human</span>
###xml 68 73 <span type="species:ncbi:9606">Human</span>
###xml 454 462 <span type="species:ncbi:9606">patients</span>
###xml 499 507 <span type="species:ncbi:9606">patients</span>
###xml 539 547 <span type="species:ncbi:9606">patients</span>
Phenotypic characterization of human CD103+ and CD103- MLN DCs. (A) Human MLN section stained with anti-DC-LAMP (FITC), CD103 (Cy3), and IgG (Cy5) antibody to identify B cell follicles for orientation in the LN. CD103+ DCs (yellow). Bar, 100 mum. (B) Percent of DCs expressing CD103 in normal and Crohn's MLN, as determined by flow cytometry using the DC gatings described in Fig. S2 A (available at ). Filled squares, normal MLN (bladder reconstruction patients; n = 9); open squares, colon cancer patients (n = 4); triangles, SB Crohn's patients (n = 6). (C and D) CD40 and CD83 expression on CD103+ and CD103- normal MLN DCs using the gatings described in Fig. S2 A (available at ). Representative FACS plots (C) and mean and SD (D) of three (CD83) or four (CD40) independent experiments. **, P < 0.01. Results are normalized within each experiment to the percent expression on CD103+ DCs.
###end p 30
###begin p 31
###xml 15 16 15 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 0 67 0 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Human MLN CD103<sup>+</sup> DCs efficiently induce CCR9 on responding T cells.</bold>
###xml 112 113 105 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 139 140 132 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 149 150 142 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 380 381 373 374 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 406 407 399 400 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 653 654 639 640 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 663 664 649 650 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 814 816 793 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 818 820 797 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 822 824 801 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib54">54</xref>
###xml 964 965 936 937 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 982 987 <span type="species:ncbi:9606">human</span>
Human MLN CD103+ DCs efficiently induce CCR9 on responding T cells. (A-C) CCR9 and alpha4beta7 expression on CD8+ T cells primed with CD103+ or CD103- DCs from normal (A-C) or SB Crohn's (B and C) MLN. DCs were sorted as described in Materials and methods and Fig. S2 B (available at ). (A) Representative flow cytometry plots. (B) CCR9 expression on T cells stimulated with CD103+ (empty symbols) or CD103- MLN DCs (filled symbols). Each symbol represents a separate experiment and horizontal line represents the mean value. Boxes in A show the gates that were used to assess CCR9 expression. (C) alpha4beta7 expression on T cells stimulated with CD103+ or CD103- MLN DCs. Normal, mean and SD of four experiments; Crohn's, mean of two experiments. Because alpha4beta7 is induced in a cell cycle-dependent manner (12, 13, 54), alpha4beta7 expression was assessed on cells that had divided six to nine times (arrows in A). (D) Gut-homing receptor induction by CD103+ DCs from normal human MLN was inhibited by addition of 1 muM of the pan-RAR antagonist LE540 to the cell cultures. Results are mean and SD of four separate experiments. ***, P < 0.001.
###end p 31
###begin title 32
DISCUSSION
###end title 32
###begin p 33
###xml 70 72 70 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 74 76 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 78 80 78 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 118 119 118 119 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 124 125 124 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 230 231 230 231 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 301 302 301 302 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 405 406 405 406 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 415 416 415 416 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 468 469 468 469 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 548 549 548 549 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 591 592 591 592 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 873 874 873 874 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1048 1049 1048 1049 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1197 1198 1197 1198 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1089 1094 <span type="species:ncbi:9606">human</span>
###xml 1165 1171 <span type="species:ncbi:10090">murine</span>
###xml 1268 1273 <span type="species:ncbi:9606">human</span>
Recent studies have highlighted an important role for intestinal DCs (12, 14, 18) and, in particular, intestinal CD103+ DC (8, 15-17, 21) in inducing RAR signaling and gut-homing receptor expression on responding T cells and FoxP3+ Treg differentiation. In this paper, we show that SI-LP and MLN CD103+ DCs induce greater RAR signals and more efficiently induce CCR9 in responding T cells than other CD103+ or CD103- DC populations. We provide evidence that most CD103+ SI-LP DCs develop directly from a circulating DC precursor, and not from CD103- SI-LP DCs, and that the majority of CD103+ MLN DCs represent a SI-LP-derived migratory population that plays a critical role in presenting orally derived soluble antigen to T cells. Thus, these cells presumably capture orally applied antigens locally in the SI and subsequently migrate into the MLN. In contrast, most CD103- MLN DCs appear to represent a blood-derived LN population that can proliferate in the MLN and present systemic antigen to T cells. Critically, we also demonstrate that CD103+ DCs are present in normal and inflamed human MLN and display similar phenotypic and functional properties to their murine counterparts. Thus, CD103+ MLN DCs represent a potential novel target population for regulating human intestinal immune responses.
###end p 33
###begin p 34
###xml 226 227 226 227 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 258 259 258 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 296 297 296 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 457 458 457 458 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 580 582 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">34</xref>
###xml 707 709 707 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib35">35</xref>
###xml 1060 1061 1060 1061 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1105 1112 1105 1112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">aldh1a2</italic>
###xml 1153 1154 1153 1154 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1318 1325 1318 1325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">aldh1a2</italic>
###xml 1358 1365 1358 1365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">aldh1a2</italic>
###xml 1552 1553 1545 1546 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1563 1565 1556 1558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">36</xref>
###xml 1600 1603 1589 1592 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1659 1660 1648 1649 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1695 1702 1684 1691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">aldh1a2</italic>
###xml 1704 1706 1693 1695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">36</xref>
###xml 1790 1791 1779 1780 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1826 1829 1811 1814 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1907 1908 1892 1893 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2042 2043 2027 2028 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2223 2225 2208 2210 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 2250 2252 2235 2237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 2281 2284 2266 2269 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1604 1608 <span type="species:ncbi:10090">mice</span>
###xml 1754 1758 <span type="species:ncbi:10090">mice</span>
Our current results demonstrate that although all DCs appear to be capable of inducing limited RAR signaling in T cells, the ability to induce high RAR signaling and efficient CCR9 expression is not a general property of CD103+ DCs and, notably, not of CD103+ Co-LP DCs but of SI-LP and MLN CD103+ DCs. As the latter population appears to derive from the former (see subsequent Discussion paragraphs), these results argue for a selective imprinting of CD103+ DCs, or their immediate precursors, in the SI-LP. In this regard, vitamin A itself is primarily absorbed through the SI (34), and incubation of monocyte-derived DCs with RA imprinted on these cells the ability to induce CCR9 on responding T cells (35). This activity was blocked with a RAR antagonist, but not a RALDH inhibitor, leading to the suggestion that CCR9 induction may be mediated by RA that has been taken up and stored by DCs. Nevertheless, incubation with high concentration of RA (1,000 nM) was required for this effect, and the in vivo relevance of these findings remains unclear. CD103+ SI-LP and MLN DCs express higher levels of aldh1a2 (unpublished data) (15) than their CD103- counterparts, suggesting that their enhanced ability to induce RAR signaling may lie in an increased capacity to metabolize retinal. Although the signals inducing aldh1a2 expression and the link between aldh1a2 expression and DC-mediated RAR signaling remains unclear, addition of IL-4 to MLN DC-T cell cultures was recently found to enhance CCR9, but not alpha4beta7, expression on responding CD4+ T cells (36). Notably, MLN DCs from IL-4ralpha-/- mice displayed a reduced capacity to induce CCR9 on CD4+ T cells and had reduced levels of aldh1a2 (36), although the composition of MLN DCs in these mice was not assessed. Moreover, CD8+ T cells in the SI-LP of IL-4ralpha-/- expressed normal levels of CCR9. In the current study, the inability of CD103- SI-LP DCs to induce enhanced RAR signaling suggests that imprinting signals are not ubiquitously expressed in the SI-LP or that CD103- SI-LP DCs are incapable of responding to such signals. Notably, although CD103 expression on DCs appears to play a critical functional role in T cell-mediated regulation of CD45RBhi T cell-induced colitis (22), our experiments with CD103-/- MLN DCs demonstrate that CD103 is not required for imprinting intestinal DCs with the ability to generate gut tropic T cells.
###end p 34
###begin p 35
###xml 78 79 78 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 102 103 102 103 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 113 114 113 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 151 152 151 152 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 191 192 191 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 212 213 212 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 218 219 218 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 292 293 292 293 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 833 835 833 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 964 965 964 965 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 968 969 968 969 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 994 995 994 995 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1058 1060 1058 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">38</xref>
###xml 1193 1194 1193 1194 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1203 1204 1203 1204 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1469 1470 1469 1470 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1474 1476 1474 1476 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 1487 1488 1487 1488 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1492 1494 1492 1494 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lo</sup>
###xml 1527 1528 1527 1528 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1538 1539 1538 1539 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1564 1566 1564 1566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib39">39</xref>
###xml 715 718 <span type="species:ncbi:10116">rat</span>
###xml 952 958 <span type="species:ncbi:10090">murine</span>
###xml 1052 1056 <span type="species:ncbi:10090">mice</span>
Irrespective of the imprinting mechanism, the similar initial kinetics of BrdU+ cells within the CD103+ and CD103- LP DC populations suggest that CD103+ SI-LP DCs are not the progeny of CD103- SI-LP (MHC class II+CD11c+) DCs. Moreover, our intestinal transplant experiments suggest that CD103+ SI-LP DCs do not derive from resident proliferating precursors within the LP but are continually replenished by blood-borne precursors seeding the LP. This result, however, should be interpreted with a degree of caution, as we cannot at this point rule out that inflammation associated with the transplant surgery triggers the release of donor-derived DC precursors that are replaced by precursors of host origin. In the rat, small numbers of DCs were found in intestinal lymph that originated from adoptively transferred blood monocytes (37), indicating that at least some intestinal-LP migratory DCs are monocyte derived. Consistent with this possibility, murine CD11b+Gr1+ monocytes generate CD11c+ LP cells when transferred into LP-DC-depleted recipient mice (38), although further phenotypic analysis of the resulting population was not performed. It also remains to be determined whether CD103+ or CD103- SI-LP DCs derive from distinct DC precursors in the steady state or whether the same DC precursor population can generate both subsets depending on the microenvironmental signals they receive. The former possibility is supported by the recent observation that CCR2+Ly6Chi and CX3CR1+Ly6Clo monocyte subsets replenish CD103+ and CD103- lung DCs, respectively (39).
###end p 35
###begin p 36
###xml 75 76 75 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 86 87 86 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 167 168 167 168 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 174 175 174 175 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 351 352 351 352 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 511 513 511 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 515 517 515 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 519 521 519 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">40</xref>
###xml 523 525 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib41">41</xref>
###xml 533 534 533 534 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 543 544 543 544 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 574 576 574 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 624 627 624 627 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 634 636 634 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 638 640 638 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 678 679 678 679 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 688 689 688 689 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 748 750 748 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib42">42</xref>
###xml 751 753 751 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib44">44</xref>
###xml 842 844 842 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib42">42</xref>
###xml 845 847 845 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib44">44</xref>
###xml 897 898 897 898 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 390 394 <span type="species:ncbi:10090">mice</span>
###xml 628 632 <span type="species:ncbi:10090">mice</span>
Our current results also provide strong evidence that the majority of CD103+ and CD103- MLN DCs derive from distinct populations of DCs. The delayed appearance of BrdU+ CD103+ DCs in MLN compared with the SI-LP is compatible with the idea that most of these cells represent a tissue-derived migratory population. Consistent with this hypothesis, CD103+ DC numbers are reduced in the MLN of mice lacking CCR7, a chemokine receptor which is required for DC migration from peripheral tissues into the draining LN (17, 24, 40, 41). CD103+ Langerin+ DCs are present in the lung (23) and are reduced in numbers in the LDLN of CCR7-/- mice (24, 25). Furthermore, a radiosensitive CD103+ Langerin+ DC population was recently identified in the skin dermis (42-44) that migrates to the skin, draining LN in the steady state in a CCR7-dependent manner (42-44). Together, these results suggest that most CD103+ DCs in intestinal and extraintestinal LN represent tissue-derived migratory DCs.
###end p 36
###begin p 37
###xml 27 28 27 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 38 39 38 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 45 46 45 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 230 231 230 231 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 337 339 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib45">45</xref>
###xml 341 343 341 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib46">46</xref>
###xml 640 642 640 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib47">47</xref>
###xml 643 645 643 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib50">50</xref>
###xml 686 687 674 675 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 712 713 700 701 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 837 838 813 814 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 844 845 820 821 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 859 860 835 836 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 938 939 914 915 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
In marked contrast to CD103+ DCs, BrdU+ CD103- DCs accumulated with at least as rapid kinetics in the MLN as in the SI-LP, suggesting that the majority of these cells in MLN represent a resident population. In addition, most CD103- LN DCs displayed an immature phenotype under steady state, a proposed characteristic of LN-resident DCs (45, 46). Several mechanisms have been reported to help maintain the splenic and LN-resident DC compartment in the steady state. These include continuous recruitment of DC precursors from the blood and differentiation from tissue resident DC precursors, as well as a limited expansion of DCs themselves (47-50). We found that approximately6% of CD103- DCs in the MLN were Ki67+ at any one time and were thus actively proliferating. Further, in combined Ki67 and BrdU staining, approximately60% of BrdU+ CD103- DCs were Ki67+ 3 h after BrdU administration, suggesting that in the steady state, the CD103- DC population is maintained in part through homeostatic proliferation and in part through the entry of DC precursors from the blood.
###end p 37
###begin p 38
###xml 32 33 32 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 273 274 273 274 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 284 286 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 364 365 364 365 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 615 618 615 618 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 649 651 649 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 653 655 653 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib51">51</xref>
###xml 694 695 694 695 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 619 623 <span type="species:ncbi:10090">mice</span>
Our observations that only CD103+ MLN DCs induce OT-I and OT-II proliferation after oral OVA administration demonstrate a key role for these cells in cross-presenting orally derived soluble antigen and confirm the importance of these cells in presenting oral antigen to CD4+ T cells (15). We further show that this is not caused by a defect in the ability of CD103- MLN DCs to present antigen, as these cells primed OT-I and, especially, OT-II cells after i.p. administration of antigen. These results, together with previous observations that OT-I and OT-II cells fail to respond to orally administered OVA in CCR7-/- mice but respond to i.p. OVA (17, 51), provides further evidence that CD103+ MLN DCs represent the major tissue-derived migratory DC population that presents soluble luminal antigen to T cells.
###end p 38
###begin p 39
###xml 168 170 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 261 262 261 262 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 313 316 313 316 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 424 425 424 425 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 537 538 537 538 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 787 790 773 776 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 848 850 827 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 1166 1168 1131 1133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib52">52</xref>
###xml 1169 1171 1134 1136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib54">54</xref>
###xml 1211 1212 1176 1177 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1292 1293 1257 1258 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 317 321 <span type="species:ncbi:10090">mice</span>
###xml 791 795 <span type="species:ncbi:10090">mice</span>
###xml 1373 1377 <span type="species:ncbi:10090">mice</span>
We have previously demonstrated that CCR9 is more efficiently induced on adoptively transferred OT-I cells in the MLN after oral compared with i.p. OVA administration (12). Thus, efficient induction of CCR9 correlates with enhanced antigen presentation by CD103+ DCs. Further, OT-I cells primed in the MLN of CCR7-/- mice after administration of OVA and adjuvant i.p. fail to express CCR9 (12). Thus, reduced levels of CD103+ DCs in the MLN correlate with reduced CCR9 induction. Together, these correlations strongly indicate that CD103+ MLN DCs are required for efficient CCR9 induction in vivo. Although alpha4beta7 induction is also greatest under conditions of highest CCR9 induction, alpha4beta7 is also induced on OT-I cells after i.p. OVA administration alone in both WT and CCR7-/- mice. Because induction of alpha4beta7 is RAR dependent (21), these results suggest that RAR signaling provided by additional cells in the MLN is sufficient to induce some alpha4beta7 expression on T cells primed at this site. Indeed, alpha4beta7 is induced on proliferating antigen-specific T cells in the MLN after i.p. injection of antigen-loaded BM or peripheral LN DCs (52-54). Determining the precise role of CD103+ MLN DC-mediated RAR signaling in the generation of gut tropic T cells and FoxP3+ T reg cell differentiation will likely require analysis of immune responses in mice selectively depleted of this unique subset of DCs.
###end p 39
###begin p 40
###xml 184 185 184 185 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 365 366 365 366 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 550 551 550 551 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 741 742 741 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 879 880 879 880 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 930 931 930 931 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 71 76 <span type="species:ncbi:9606">human</span>
###xml 172 178 <span type="species:ncbi:10090">murine</span>
###xml 352 358 <span type="species:ncbi:9606">humans</span>
###xml 440 448 <span type="species:ncbi:9606">patients</span>
###xml 493 498 <span type="species:ncbi:10090">mouse</span>
###xml 572 577 <span type="species:ncbi:9606">human</span>
###xml 834 839 <span type="species:ncbi:9606">human</span>
###xml 989 997 <span type="species:ncbi:9606">patients</span>
###xml 1078 1084 <span type="species:ncbi:10090">murine</span>
###xml 1199 1204 <span type="species:ncbi:9606">human</span>
To our knowledge, the phenotype and function of distinct DC subsets in human intestinal LN has not previously been examined. Given the unique functional characteristics of murine CD103+ MLN DCs and their potentially important role in regulating intestinal immune responses, it was of central importance to determine the relevance of this population in humans. CD103+ DCs were readily detected in MLN, draining both healthy SI and the SI of patients with Crohns disease. These cells, as in the mouse, displayed a more mature phenotype than their CD103- counterparts. Total human MLN, but not splenic or liver, DCs have previously been shown to efficiently induce gut-homing receptors on responding B cells through an RAR-dependent mechanism (8). Importantly, we demonstrate that the ability to induce CCR9 is not a general property of human MLN DCs but, again, selective for CD103+ MLN DCs. Moreover, the selective ability of CD103+ MLN DCs to induce CCR9 was maintained in Crohn's disease patients. Together, these results highlight the relevance of studying this population in murine models of intestinal homeostasis and inflammation and the future possibility of targeting these cells to regulate human intestinal immune responses in health and disease.
###end p 40
###begin title 41
MATERIALS AND METHODS
###end title 41
###begin title 42
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 9 14 <span type="species:ncbi:9606">human</span>
Mice and human tissues
###end title 42
###begin p 43
###xml 146 148 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 262 265 262 265 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 140 144 <span type="species:ncbi:10090">mice</span>
###xml 286 290 <span type="species:ncbi:10090">mice</span>
###xml 388 392 <span type="species:ncbi:10090">Mice</span>
C57BL/6 (Taconic), DR5 (provided by R. Blomhoff, Institute of Basic Medical Science, University of Oslo, Norway), OT-I, OT-II, and DR5.OT-I mice (21) were bred and maintained at the Biomedical Center animal facility (Lund University, Lund, Sweden). BALB/c, CD103-/- BALB/c, and DO11.10 mice were bred and maintained in animal Facilities at the University of Oxford (Oxford, England, UK). Mice between 6 and 14 wk of age were used for experiments. Animal experiments were performed in accordance with guidelines from Lund/Malmo Animal Ethics Committee, the review board of the Hannover Medical School, or the UK Animals (Scientific Procedures) Act of 1986 where appropriate.
###end p 43
###begin p 44
###xml 88 89 88 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 124 125 124 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 198 199 198 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 30 38 <span type="species:ncbi:9606">patients</span>
###xml 164 172 <span type="species:ncbi:9606">patients</span>
###xml 246 253 <span type="species:ncbi:9606">patient</span>
Normal MLN were obtained from patients undergoing bladder reconstruction by cystectomy (n = 9) or surgery for colon cancer (n = 4). Inflamed MLN were obtained from patients with SB Crohn's disease (n = 6). All tissues were obtained with informed patient consent and in accordance with local ethical approval from the Regional Ethics committee in Lund (Sweden) and the South Birmingham Research Ethics committee (England, UK).
###end p 44
###begin title 45
Reagents
###end title 45
###begin p 46
###xml 365 381 362 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli</italic>
###xml 365 381 <span type="species:ncbi:562">Escherichia coli</span>
R10 medium contained the following reagents, all from Invitrogen: RPMI-1640, 10% FCS, 10 mM Hepes, 1 mM sodium pyruvate, 50 muM mercaptoethanol, 100 U/ml penicillin, 100 mug/ml streptomycin, and 50 mug/ml gentamicin. HBSS was obtained from Invitrogen. Synthetic pOVAs (OT-I, SIINFEKL; and OT-II, ISQAVHAAHAEINEAGR) were obtained from Innovagen. OVA grade VII, LPS (Escherichia coli, serotype 055:B55), DNase I, and collagenase type IV and VIII were obtained from Sigma-Aldrich. OVA was purified using Detoxi-Gel Endotoxin removal gel (Thermo Fisher Scientific). CFSE (Sigma-Aldrich) and LE540 (Wako Chemicals USA, Inc.) were dissolved in DMSO.
###end p 46
###begin title 47
Cell staining reagents
###end title 47
###begin p 48
###xml 570 572 563 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib56">56</xref>
###xml 42 48 <span type="species:ncbi:10090">murine</span>
###xml 207 210 <span type="species:ncbi:10116">rat</span>
###xml 431 436 <span type="species:ncbi:10090">mouse</span>
###xml 448 453 <span type="species:ncbi:9606">human</span>
###xml 614 620 <span type="species:ncbi:9793">donkey</span>
###xml 626 631 <span type="species:ncbi:9606">human</span>
###xml 696 701 <span type="species:ncbi:10090">mouse</span>
###xml 707 710 <span type="species:ncbi:10116">rat</span>
###xml 742 747 <span type="species:ncbi:10090">mouse</span>
###xml 753 756 <span type="species:ncbi:10116">rat</span>
The following reagents were used to stain murine cells: unconjugated or directly conjugated anti-CD103 (M290), anti-alpha4beta7 (DATK32), anti-CD62L (MEL-14), anti-MHC class II (2G9), anti-CD11c (N418), and rat IgG2a and IgG2b isotype controls (BD Biosciences); perCP-Cy5.5, Alexa 700-conjugated anti-CD11c (N418), and Pacific blue-conjugated anti-MHC Class II (M5/114.15.2; BioLegend); anti-CCR7 (4B12; eBiosciences); recombinant mouse E-selectin human Fc chimera (R&D Systems); anti-FcRII/III (2.4G2), anti-CD40 (FGK45), anti-CD86 (GL1), and anti-CCR9 antibody (7E7, (56); purified from hybridomas); Cy5-labeled donkey anti-human IgG F(ab')2 (Jackson ImmunoResearch Laboratories); biotinylated mouse anti-rat IgG2a (RG7/1.30), biotinylated mouse anti-rat IgG2b (G15-337), PE-labeled Ki67, streptavidin-conjugated PE, PECy7, PerCP Cy5.5, and the BrdU FITC flow kit (BD Biosciences); streptavidin-alexa 488 (Invitrogen); and DAPI (Sigma-Aldrich).
###end p 48
###begin p 49
###xml 379 380 376 377 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 42 47 <span type="species:ncbi:9606">human</span>
###xml 671 674 <span type="species:ncbi:157914">Ber</span>
###xml 792 797 <span type="species:ncbi:10090">mouse</span>
###xml 803 808 <span type="species:ncbi:9606">human</span>
The following reagents were used to stain human DCs: APC-conjugated anti-CD40 (5C3), APC-Cy7-conjugated anti-HLA-DR (L243), PE-Cy5-conjugated anti-beta7 (FIB504), and APC-Cy7-conjugated anti-CD8 (SK7; BD Biosciences); PE-Cy7-conjugated anti-CD11c (3.9), biotinylated or PE-Cy5-conjugated anti-CD83 (HB15e), PE-conjugated anti-CD103 (BLy7), APC/PE/PE-Cy5- or biotin-conjugated IgG1 isotype controls, and FITC-conjugated anti-CD3 (UCHT1), -CD14 (61D3), -CD16 (CB16), -CD19 (HIB19), and -CD56 (MEM188; eBiosciences); PE-Cy7-conjugated anti-CD3 (UCHT1; Beckman Coulter); APC-conjugated anti-CCR9 (R&D Systems); PE-conjugated anti-CD8 (DK2) and FITC/PE-conjugated anti-CD103 (Ber-ACT8; Dako); FITC/Cy7-conjugated anti-CD11c (BU15) and FITC/Cy5-conjugated anti-HLA-DR (YE2/36HLK; AbD Serotec); and mouse anti-human alpha4beta7 (ACT-1; provided by M. Briskin, Millennium Pharmaceuticals, Inc.).
###end p 49
###begin title 50
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
Murine cell isolation and flow cytometry analysis
###end title 50
###begin p 51
###xml 70 72 70 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 132 133 120 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 147 148 135 136 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 160 161 148 149 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 172 173 160 161 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 183 184 171 172 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 221 222 209 210 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 322 324 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 371 383 359 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 (B&#8211;E)</xref>
###xml 524 526 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 593 594 581 582 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 654 656 642 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 658 660 646 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 755 757 743 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib55">55</xref>
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
###xml 408 412 <span type="species:ncbi:10090">mice</span>
Murine T cells and DCs were purified by MACS as previously described (17). T cell purity was 90-95%. DCs were approximately95% CD11c+ and 90% CD11c+MHC class II+. For CD103+ and CD103- DC purification, MACS-enriched CD11c+ DCs were sorted using anti-CD11c, anti-CD103, and anti-MHC class II on a FACSAria (BD Biosciences; 17). DC fractions were routinely 95-99% pure. In Fig. 1 (B-E), DCs were isolated from mice injected with FMS-like tyrosine kinase-3 ligand (Flt3L)-secreting B16 melanoma cells, as previously described (17). Such treatment does not influence the selective ability of CD103+ MLN DCs to induce CCR9 or the phenotype of intestinal DCs (17, 21). CFSE labeling of T cells and flow cytometry analysis was performed as previously described (55). Data acquisition was performed on a FACSCalibur or FACSAria (BD Biosciences) and analyzed using FlowJo software (Tree Star, Inc.).
###end p 51
###begin title 52
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human cell isolation and flow cytometry analysis
###end title 52
###begin p 53
###xml 920 921 912 913 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 1127 1128 1119 1120 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1135 1136 1127 1128 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1170 1171 1162 1163 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1181 1182 1173 1174 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1248 1249 1240 1241 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1259 1260 1251 1252 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 94 99 <span type="species:ncbi:9606">Human</span>
Lymphocytes were isolated from peripheral blood using LymphoLyte-H (Cedarlane Laboratories.). Human MLN DCs were isolated using one of two protocols: (a) MLN were cut into small pieces and incubated in R10 with 500 mug/ml collagenase IV and 50 U/ml DNase I for 10 min at 37degreesC on an orbital shaker (Innova 2300; New Brunswick Scientific) at 250 rpm. Remaining tissue was mechanically crushed and, together with the cell suspension, passed through a 70-mum cell strainer. Cells were stained and either analyzed or sorted using a FACSAria. (b) MLN pieces were mechanically disaggregated in HBSS supplemented with 5% FCS and 5 mM EDTA (Sigma-Aldrich) at 230 rpm for 5 min in a circulator (Stomacher 400; Seward). The resulting sample was passed through a fine mesh and washed with HBSS. Supernatant was mixed with OptiPrep (AxisShield) 1:3 and overlayered with 11.5% OptiPrep and HBSS. Samples were centrifuged at 600 g for 20 min and the DC fraction was harvested. Remaining lymphocytes were depleted with anti-CD3 dynabeads (Invitrogen) and DCs isolated by CD11c expression using EasySep (StemCell Technologies Inc.). CD11c+ HLA-DR+ cells were FACS sorted into CD103+ and CD103- DC fractions. Both protocols yielded similar proportions of CD103+ and CD103- MLN DCs. Data acquisition was performed using FACSAria or Cyan flow cytometer (Dako) and data analyzed using FlowJo or Summit software (Dako).
###end p 53
###begin title 54
In vitro and ex vivo cell cultures
###end title 54
###begin title 55
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
Murine cell cultures.
###end title 55
###begin p 56
###xml 113 114 107 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 133 134 127 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 399 401 392 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 561 563 554 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 596 597 589 590 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 607 608 600 601 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 674 675 667 668 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 703 704 696 697 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 653 657 <span type="species:ncbi:10090">mice</span>
DCs were pulsed with 2 nM or 200 pM SIINFEKL peptide for 1 h at 37degreesC, washed extensively, and incubated (105 cells) with 2 x 105 CFSE-labeled OT-I cells in flat bottom 96-well plates (Thermo Fisher Scientific) in 200 mul of complete R10 medium. The phenotype of responding OT-I cells was assessed by flow cytometry after 3.5 d or after expansion for an additional 2 d as previously described (21). For luciferase measurements, DR-5.OT-I cells and antigen-pulsed DCs were cocultured and luciferase activity was assessed after 22 h as previously described (21). For ex vivo DC cultures, CD103+ and CD103- MLN DCs were FACS sorted from OVA-immunized mice and cultured (105 cells) together with 2 x 105 CFSE-labeled OT-I cells for 3.5 d before analysis.
###end p 56
###begin title 57
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human cell cultures.
###end title 57
###begin p 58
###xml 51 52 51 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 69 70 69 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 79 80 79 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 216 217 209 210 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
CFSE-labeled PBL were cultured together with 5 x 105 allogeneic CD103- or CD103+ MLN DCs at a 1:1 ratio in R10 medium supplemented with 400 IU/ml IL-2 (Proleukin). Proliferation and CCR9/alpha4beta7 expression on CD8+ T cells were measured after 7 d by flow cytometry.
###end p 58
###begin title 59
Small bowel transplantation
###end title 59
###begin p 60
###xml 71 73 71 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
The small bowel transplantation was performed as previously described (32).
###end p 60
###begin title 61
Immunohistochemistry
###end title 61
###begin title 62
###xml 12 17 <span type="species:ncbi:10090">mouse</span>
Staining of mouse tissue.
###end title 62
###begin p 63
###xml 48 50 48 50 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
Staining was performed as previously described (17) using CD11c-APC (N418), CD103-PE (M290), MHC class II-biotin (2G9), DAPI, and streptavidin-Alexa 488.
###end p 63
###begin title 64
###xml 12 17 <span type="species:ncbi:9606">human</span>
Staining of human tissue.
###end title 64
###begin p 65
###xml 211 215 <span type="species:ncbi:9925">goat</span>
###xml 221 226 <span type="species:ncbi:10090">mouse</span>
###xml 537 543 <span type="species:ncbi:9793">donkey</span>
###xml 549 554 <span type="species:ncbi:9606">human</span>
Acetone-fixed MLN sections were blocked with 10% NGS (Sigma-Aldrich) and avidin-biotin blocking kit (Vector Laboratories). Tissue was stained with anti-DC-LAMP (104.G4; Beckman Coulter) followed by FITC-labeled goat anti-mouse antibody (Jackson ImmunoResearch Laboratories). After washing and blocking with 10% NMS, sections were stained with biotin anti-CD103 (28C12) and visualized using a tyramide signal amplification kit (PerkinElmer Life Science) and Cy3-conjugated streptavidin (Biosite). Sections were costained with Cy5-labeled donkey anti-human IgG F(ab')2 (Jackson ImmunoResearch Laboratories). Images were acquired with a microscope (Axiovert 200M; Carl Zeiss, Inc.) and Volocity software (Improvision) or AxioVision 4.0 software (Carl Zeiss, Inc.).
###end p 65
###begin title 66
Statistical analysis
###end title 66
###begin p 67
###xml 82 83 82 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 125 126 125 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
Statistical analyses were performed using paired or unpaired two-tailed Student's t test with Welch correction or one sample t test where appropriate.
###end p 67
###begin title 68
Online supplemental material
###end title 68
###begin p 69
###xml 75 76 75 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 86 87 86 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 198 199 198 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 209 210 209 210 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 379 380 372 373 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 390 391 383 384 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 368 373 <span type="species:ncbi:9606">human</span>
Fig. S1 shows the flow cytometry gating strategy used for identifying CD103+ and CD103- DCs and the maturation phenotype of these populations in different tissues. Fig. S2 shows the ability of CD103+ and CD103- DC subsets to induce alpha4beta7 and E-selectin ligand on responding T cells. Fig. S3 displays the flow cytometry gating strategy used to phenotype and sort human CD103+ and CD103- intestinal DCs. Online supplemental material is available at .
###end p 69
###begin title 70
Supplementary Material
###end title 70
###begin title 71
[ Supplemental Material Index]
###end title 71
###begin p 72
###xml 151 155 <span type="species:ncbi:10090">mice</span>
The authors would like to thank Professor R. Blomhoff (University of Oslo, Norway) and Cgene (Cgene AS, Oslo, Norway) for providing the DR5-luciferase mice. We also wish to thank Professors A. Mowat (University of Glasgow, UK) and D. Adams (Birmingham University, UK) for valuable input, Dr T. Ismail (Birmingham University) and Prof W. Mansson (Lund University Hospital) for intestinal samples, and Ann-Charlotte Selberg for valuable technical assistance.
###end p 72
###begin p 73
W.W. Agace is supported by grants from the Swedish Medical Research Council, the Crafoordska, Wenner-Gren, Osterlund, LEO Pharma A/S, Ake Wiberg, Nanna Svartz, and Kocks Foundations, the Royal Physiographic Society, the Wellcome Trust, and the Swedish Foundation for Strategic Research INGVAR II program. F. Powrie is funded by the Wellcome Trust and J.L. Coombes by an MRC studentship.
###end p 73
###begin p 74
The authors have no conflicting financial interests.
###end p 74

